Catalio Capital Management’s Parabilis Medicines Inc PBLS Stock Holding History

Catalio Capital Management’s Portfolio PBLS Stock Details PBLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$22.6M	Buy	+824,043	New	+$22.8M	4.24%	8

Other funds holding PBLS

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

venBio Partners San Francisco, California $519M AUM 339.42% 1-Year Est. Return

Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Catalio Capital Management's PBLS Position: Q2 2026 in Review

Catalio Capital Management opened a new position in Parabilis Medicines Inc (PBLS) in Q2 2026: 824,043 shares worth $22.6M. The stake represents 4.24% of the portfolio and ranks #8 among its holdings.

79 funds tracked by Wall St. Rank hold PBLS as of Q2 2026.

Catalio Capital Management held 824,043 shares of Parabilis Medicines Inc worth $22.6M as of Q2 2026.
Parabilis Medicines Inc was a new Catalio Capital Management position in Q2 2026.
Parabilis Medicines Inc made up 4.24% of Catalio Capital Management's portfolio in Q2 2026, its #8 holding.
79 funds tracked by Wall St. Rank held Parabilis Medicines Inc as of Q2 2026.

Based on Catalio Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.